Using droplet digital PCR to analyze MYCN and ALK copy number in plasma from patients with neuroblastoma.

ABSTRACT: The invasive nature of surgical biopsies deters sequential application, and single biopsies often fail to reflect tumor dynamics, intratumor heterogeneity and drug sensitivities likely to change during tumor evolution and treatment. Implementing molecular characterization of cell-free neuroblastoma-derived DNA isolated from blood plasma could improve disease assessment for treatment selection and monitoring of patients with high-risk neuroblastoma. We established droplet digital PCR (ddPCR) protocols for MYCN and ALK copy number status in plasma from neuroblastoma patients. Our ddPCR protocol accurately discriminated between MYCN and ALK amplification, gain and normal diploid status in a large panel of neuroblastoma cell lines, and discrepancies with reported

SUBMITTER: Lodrini M 

PROVIDER: S-EPMC5689606 | biostudies-literature | 2017 Oct

REPOSITORIES: biostudies-literature